Unveiling the Potential Drug Target and Biomarker UCLK1 (UCKL1_HUMAN)

Target Name: UCKL1

NCBI ID: G54963

UCKL1

Unveiling the Potential Drug Target and Biomarker UCLK1 (UCKL1_HUMAN)

Unlock the Potential of UCLK1: A Drug Target and Biomarker

Uncovering new drug targets and biomarkers is a critical aspect of drug development. It not only helps in the treatment of diseases but also paves the way for the development of new diagnostic tools. One such target, UCLK1 (UCKL1_HUMAN), has shown promising results in various cellular and biological studies, making it an attractive candidate for drug development. In this article, we will delve into the potential of UCLK1 as a drug target and biomarker.

Understanding UCLK1: The gene and its functions

The UCLK1 gene, located on chromosome 12, is a non-coding RNA molecule that plays a critical role in various cellular processes. It is a key regulator of cell adhesion, migration, and invasion, and has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. UCLK1 has four splice variants, UCLK1-long, UCLK1-middle, UCLK1-short, and UCLK1-long splice variants, which give rise to different isoforms of UCLK1 protein.

Expression of UCLK1 in various tissues and cells

UCLK1 is expressed in various tissues and cells throughout the body, including the brain, heart, liver, and pancreas. It is highly expressed in the brain, where it is the highest expressed gene in the brain. UCLK1 is also expressed in the heart, where it is downregulated compared to other tissues. In the liver and pancreas, UCLK1 is expressed at moderate levels.

Functional validation of UCLK1 as a drug target

Several studies have validated the potential of UCLK1 as a drug target. One of the earliest studies investigated the effects of UCLK1 inhibitors on cancer cell growth and migration. The results showed that UCLK1 inhibitors significantly inhibited the growth and migration of cancer cells, suggesting that UCLK1 may be a promising drug target for cancer treatment.

Another study investigated the role of UCLK1 in neurodegenerative diseases. The results showed that UCLK1 was highly expressed in the brains of individuals with Alzheimer's disease and that inhibition of UCLK1 using small interfering RNA (siRNA) significantly improved memory and learning tasks in these individuals.

In addition, UCLK1 has also been shown to be involved in the development and progression of various developmental disorders. A study by researchers at the University of California, Irvine found that UCLK1 was highly expressed in the brains of individuals with Down syndrome and that inhibition of UCLK1 using RNA interference improved cognitive function and social interaction in these individuals.

Furthermore, there is evidence to suggest that UCLK1 may be a potential biomarker for various diseases. For instance, a study by researchers at the University of California, San Diego found that UCLK1 was highly expressed in the brains of individuals with multiple sclerosis and that downregulation of UCLK1 using RNA interference improved the severity of symptoms in these individuals.

The potential of UCLK1 as a drug target

The potential of UCLK1 as a drug target is high due to its various functions in various biological processes. One of the primary targets of UCLK1 is cell adhesion and migration. UCLK1 has been shown to regulate the actin-associated protein 2 (ADP-ribosome) complex, which is involved in the regulation of cell adhesion and migration.

Another potential target of UCLK1 is the regulation of cell proliferation. UCLK1 has been shown to play a role in the regulation of cell proliferation by controlling the activities of the transcription factors

Protein Name: Uridine-cytidine Kinase 1 Like 1

Functions: May contribute to UTP accumulation needed for blast transformation and proliferation

The "UCKL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UCKL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets